U. Baumgartner et al., DIFFERENT PROTECTIVE EFFECTS OF TAUROURSODEOXYCHOLATE, URSODEOXYCHOLATE, AND 23-METHYL-URSODEOXYCHOLATE AGAINST TAUROLITHOCHOLATE-INDUCED CHOLESTASIS, Digestive diseases and sciences, 41(2), 1996, pp. 250-255
The coinfusion of tauroursodeoxycholate (TUDC) prevents taurolithochol
ate (TLC)-induced cholestasis. 23-Methyl-ursodeoxycholate (MUDC) is a
side-chain derivative of ursodeoxycholate (UDC). If conjugation with t
aurine is important for the protective effect of UDC, then MUDC may no
t be as able as TUDC to prevent TLC-induced cholestasis since it is po
orly amidated by the liver. To answer this question, isolated livers o
f adult Sprague-Dawley rats were coinfused with MUDC (UDC, TUDC) and T
LC. After 15 min, inflow rates of the bile acids were doubled, In furt
her experiments taurine in excess was added to the coinfused bile acid
s. The uptake of bile acids was >90% in all groups, irrespective of wh
ether they were perfused alone or in combination. Single perfusion of
TLC caused a rapid decrease in bile flow, UDC and MUDC were hyperchole
retic; TUDC moderately choleretic. During coinfusion experiments, TUDC
not only completely abolished cholestasis but in addition increased b
ile flow and biliary bile acid secretion. UDC did prevent TLC cholesta
sis at the lower inflow rates. At high inflow rates, bile flow decreas
ed significantly. Addition of taurine to this bile acid combination di
d not significantly improve the anticholestatic effect of UDC. At low
and high infusion rates of MUDC, cholestasis induced by TLC was reduce
d very little. Cumulative bile flow over 30 min fell by approximate to
70% as compared to that of singly perfused MUDC. Addition of taurine
to the coinfused MUDC/TLC slightly, but significantly, improved the an
ticholestatic effect of MUDC. Since MUDC is by far less protective tha
n UDC (and TUDC) despite similar physicochemical properties, it is con
cluded that taurine conjugation of UDC seems to be a prerequisite to p
revent TLC-induced cholestasis, The results imply that treatment of ch
olestatic liver diseases with taurine-conjugated UDC might be more app
ropriate than with unconjugated UDC in cases where taurine conjugation
is defective or where taurine depletion has occurred.